Oncodesign, UCB collaborate on neurodegenerative diseases

Thursday, November 14, 2013

Oncodesign, a drug discovery company and oncology pharmacology service provider, has entered into a research collaboration and exclusive license option with UCB, a global biopharmaceutical provider specialized in neurology and immunology. The collaboration will bring innovative therapeutic solutions to patients suffering from neurodegenerative disorders. Oncodesign will apply its Nanocyclix technology on a kinase target selected by UCB, with the aim of discovering potent and selective inhibitors that cross the blood brain barrier.

[Read More]